Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  1,557 results for ""Zoledronic Acid""

Your Filters

Subject : denosumab
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

[Hyperparathyroidism in patients with low bone mineral density treated with zoledronic acid or denosumab].

Subjects: Denosumab*/Denosumab*/Denosumab*/therapeutic use ; Denosumab*/Denosumab*/Denosumab*/adverse effects ; Zoledronic Acid*/Zoledronic Acid*/Zoledronic Acid*/therapeutic use

  • Source: Medicina clinica [Med Clin (Barc)] 2024 Dec 27; Vol. 163 (12), pp. 595-599. Date of Electronic Publication: 2024 Oct 09.Publisher: Elsevier España Country of Publication: Spain NLM ID: 0376377 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Efficacy and Safety of Denosumab vs Zoledronic Acid in OI Adults: A Prospective, Open-Label, Randomized Study.

  • Authors : Lin X; Department of Endocrinology, National Health Commission Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.; Hu J

Subjects: Denosumab*/Denosumab*/Denosumab*/therapeutic use ; Denosumab*/Denosumab*/Denosumab*/adverse effects ; Denosumab*/Denosumab*/Denosumab*/administration & dosage

  • Source: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2024 Jun 17; Vol. 109 (7), pp. 1873-1882.Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Zoledronate Sequential Therapy After Denosumab Discontinuation to Prevent Bone Mineral Density Reduction: A Randomized Clinical Trial.

  • Authors : Lee CC; Department of Orthopedic Surgery, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei, Taiwan.

Subjects: Zoledronic Acid*/Zoledronic Acid*/Zoledronic Acid*/therapeutic use ; Zoledronic Acid*/Zoledronic Acid*/Zoledronic Acid*/administration & dosage ; Denosumab*/Denosumab*/Denosumab*/therapeutic use

  • Source: JAMA network open [JAMA Netw Open] 2024 Nov 04; Vol. 7 (11), pp. e2443899. Date of Electronic Publication: 2024 Nov 04.Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

[Analysis of the efficacy and safety of bone disease treatment in patients with newly diagnosed multiple myeloma treated with denosumab or zoledronic acid].

  • Authors : Ma Y; Department of Lymphoma & Plasma Cell Disease, Senior Department of Hematology, the Fifth Medical Center of PLA General Hospital, Beijing 100071, China.; Xiao XB

Subjects: Zoledronic Acid*/Zoledronic Acid*/Zoledronic Acid*/administration & dosage ; Denosumab*/Denosumab*/Denosumab*/adverse effects ; Denosumab*/Denosumab*/Denosumab*/administration & dosage

  • Source: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi [Zhonghua Xue Ye Xue Za Zhi] 2024 Apr 14; Vol. 45 (4), pp. 345-350.Publisher: Chinese Medical Association Country of Publication: China NLM ID: 8212398 Publication Model: Print Cited Medium: Print ISSN: 0253-2727

Record details

Read More Add to Saved list
×
Academic Journal

Differential effects of teriparatide, denosumab and zoledronate on hip structural and mechanical parameters in osteoporosis; a real-life study.

  • Authors : Jaarah N; Department of Chemical Pathology and Metabolic Medicine, St Thomas' Hospital, 5Th Floor, North Wing, Lambeth Palace Road, London, UK.; Osteoporosis Unit, Guy's Hospital, London, SE1 7EH, UK.

Subjects: Zoledronic Acid*/Zoledronic Acid*/Zoledronic Acid*/therapeutic use ; Zoledronic Acid*/Zoledronic Acid*/Zoledronic Acid*/administration & dosage ; Zoledronic Acid*/Zoledronic Acid*/Zoledronic Acid*/pharmacology

  • Source: Journal of endocrinological investigation [J Endocrinol Invest] 2024 Jul; Vol. 47 (7), pp. 1667-1677. Date of Electronic Publication: 2024 Jan 09.Publisher: Springer Country of Publication: Italy NLM ID: 7806594 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1720-8386

Record details

Read More Add to Saved list
×
Academic Journal

Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?

  • Authors : Grassi G; Endocrine Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.; Ghielmetti A

Subjects: Zoledronic Acid*/Zoledronic Acid*/Zoledronic Acid*/administration & dosage ; Zoledronic Acid*/Zoledronic Acid*/Zoledronic Acid*/therapeutic use ; Denosumab*/Denosumab*/Denosumab*/administration & dosage

  • Source: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2024 Sep 16; Vol. 109 (10), pp. e1817-e1826.Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study.

  • Authors : Liu J; Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.; Lin X

Subjects: Denosumab*/Denosumab*/Denosumab*/therapeutic use ; Denosumab*/Denosumab*/Denosumab*/adverse effects ; Denosumab*/Denosumab*/Denosumab*/administration & dosage

  • Source: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2024 Jun 17; Vol. 109 (7), pp. 1827-1836.Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Augmentation of IFN-γ by bone marrow derived immune cells in the presence of severe suppression of IFN-γ in gingivae induced by zoledronic acid and denosumab in Hu-BLT mice model of ONJ.

  • Authors : Kaur K; Weintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Los Angeles, CA, United States.; Division of Oral Biology and Medicine, University of California School of Dentistry, Los Angeles, CA, United States.

Subjects: Denosumab*/Denosumab*/Denosumab*/adverse effects ; Interferon-gamma* ; Osteonecrosis*/Osteonecrosis*/Osteonecrosis*/chemically induced

  • Source: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2023 Jan 20; Vol. 14, pp. 1111627. Date of Electronic Publication: 2023 Jan 20 (Print Publication: 2023).Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print

Record details

Read More Add to Saved list
×
Academic Journal

Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study.

  • Authors : Buch-Larsen K; Department of Endocrinology, Diabetes and Bone-metabolic Research Unit, Rigshospitalet, Copenhagen, Denmark.; Jørgensen NR

Subjects: Breast Neoplasms/Breast Neoplasms/Breast Neoplasms/*drug therapy ; Denosumab/Denosumab/Denosumab/*therapeutic use ; Postmenopause/Postmenopause/Postmenopause/*physiology

  • Source: Scandinavian journal of clinical and laboratory investigation [Scand J Clin Lab Invest] 2021 Oct; Vol. 81 (6), pp. 425-431. Date of Electronic Publication: 2021 Jun 13.Publisher: Informa Healthcare Country of Publication: England NLM ID: 0404375 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.

  • Authors : Ikesue H; Department of Pharmacy, Kobe City Medical Center General Hospital, 2-2-1, Minatojima-Minamimachi, Chuo-ku, Kobe, 650-0047, Japan. .; Graduate School of Pharmaceutical Sciences, Kobe Gakuin University, 1-1-3 Minatojima, Chuo-ku, Kobe, 650-8586, Japan. .

Subjects: Bisphosphonate-Associated Osteonecrosis of the Jaw/Bisphosphonate-Associated Osteonecrosis of the Jaw/Bisphosphonate-Associated Osteonecrosis of the Jaw/*epidemiology ; Bone Density Conservation Agents/Bone Density Conservation Agents/Bone Density Conservation Agents/*therapeutic use ; Denosumab/Denosumab/Denosumab/*therapeutic use

  • Source: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2021 Aug; Vol. 29 (8), pp. 4763-4772. Date of Publisher: Springer International Country of Publication: Germany NLM ID: 9302957 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  1,557 results for ""Zoledronic Acid""